Purposes: The aim of this study was to evaluate whether sublobar resection could achieve recurrence and survival rates equivalent to lobectomy in high-risk elderly patients. Methods: We conducted a retrospective multicenter study that including all consecutive patients (aged >75 years) who underwent operation for clinical stage I non-small cell lung cancer (NSCLC). The clinicopathological data, postoperative morbidity and mortality, recurrence rate and vital status were retrieved. The overall survival, cancer-specific survival and disease-free survival were also assessed. Results: Two hundred and thirty-nine patients (median age 78 years) were enrolled. Lobectomies were performed in 149 (62.3 %) patients and sublobar resections in 90 (3...
Results: The in-hospital mortality was 2.7 % without difference between groups. Group B had a lower ...
Background: Recently, many surgeons have chosen sublobar resection for the curative treatment of lun...
INTRODUCTION: Surgery is the treatment of choice for early-stage lung cancer (LC). Although lobectom...
Purposes: The aim of this study was to evaluate whether sublobar resection could achieve recurrence ...
Objectives: Even though lobectomy remains the standard therapy for nonsmall- cell lung cancer (NSCL...
Background: The appropriateness of lobectomy for all elderly patients is controversial. Meanwhile, s...
population shift towards older ages will inevitably lead to more elderly patients being diagnosed wi...
Abstract Background We present a critical comparison of lobectomy and sub-lobar resection in elderly...
BackgroundRecent data have suggested possible oncologic equivalence of sublobar resection with lobec...
ObjectivesA single randomized trial established lobectomy as the standard of care for the surgical t...
Lung cancer continues to be one of the leading causes of cancer-related mortality worldwide and its ...
Objectives: Sublobar resection for early-stage lung cancer is still a controversial issue. We sought...
Surgical resection is the preferred treatment modality for eligible candidates with non-small cell l...
A best evidence topic in thoracic surgery was written according to a structured protocol. The questi...
Background: Considerable controversies exist regarding the efficacies of segmentectomy and wedge res...
Results: The in-hospital mortality was 2.7 % without difference between groups. Group B had a lower ...
Background: Recently, many surgeons have chosen sublobar resection for the curative treatment of lun...
INTRODUCTION: Surgery is the treatment of choice for early-stage lung cancer (LC). Although lobectom...
Purposes: The aim of this study was to evaluate whether sublobar resection could achieve recurrence ...
Objectives: Even though lobectomy remains the standard therapy for nonsmall- cell lung cancer (NSCL...
Background: The appropriateness of lobectomy for all elderly patients is controversial. Meanwhile, s...
population shift towards older ages will inevitably lead to more elderly patients being diagnosed wi...
Abstract Background We present a critical comparison of lobectomy and sub-lobar resection in elderly...
BackgroundRecent data have suggested possible oncologic equivalence of sublobar resection with lobec...
ObjectivesA single randomized trial established lobectomy as the standard of care for the surgical t...
Lung cancer continues to be one of the leading causes of cancer-related mortality worldwide and its ...
Objectives: Sublobar resection for early-stage lung cancer is still a controversial issue. We sought...
Surgical resection is the preferred treatment modality for eligible candidates with non-small cell l...
A best evidence topic in thoracic surgery was written according to a structured protocol. The questi...
Background: Considerable controversies exist regarding the efficacies of segmentectomy and wedge res...
Results: The in-hospital mortality was 2.7 % without difference between groups. Group B had a lower ...
Background: Recently, many surgeons have chosen sublobar resection for the curative treatment of lun...
INTRODUCTION: Surgery is the treatment of choice for early-stage lung cancer (LC). Although lobectom...